Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

[A case of massive pancreatic neuroendocrine carcinoma successfully treated with surgical resection and postoperative everolimus administration].

Mukai Y, Takeda Y, Nakahira S, Katsura Y, Kusama H, Hashimoto N, Matsushita K, Kawashima H, Hamanaka M, Kagawa Y, Takeno A, Okishiro M, Sakisaka H, Suzuki R, Egawa C, Taniguchi H, Kato T, Tamura S.

Gan To Kagaku Ryoho. 2013 Nov;40(12):1887-9. Japanese.

PMID:
24393955
2.

Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors.

Kawaguchi Y, Maruno A, Kawashima Y, Ito H, Ogawa M, Mine T.

World J Gastroenterol. 2014 Nov 14;20(42):15920-4. doi: 10.3748/wjg.v20.i42.15920.

3.

Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.

Liakakos T, Roukos DH.

Future Oncol. 2011 Sep;7(9):1025-9. doi: 10.2217/fon.11.88. No abstract available.

4.

[Two Cases of Pancreatic Neuroendocrine Tumor with Liver Metastases Successfully Treated with Multidisciplinary Therapy including Multiple Surgical Resections].

Akiyama T, Yoshitomi H, Shida T, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Takayashiki T, Kuboki S, Takano S, Okamura D, Suzuki D, Sakai N, Kagawa S, Miyazaki M.

Gan To Kagaku Ryoho. 2015 Nov;42(12):2397-9. Japanese.

PMID:
26805376
5.

Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Fernández-Cruz L, Blanco L, Cosa R, Rendón H.

World J Surg. 2008 May;32(5):904-17. doi: 10.1007/s00268-008-9467-2.

PMID:
18264824
6.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Review.

PMID:
21932937
7.

Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.

Nakayama Y, Ikeda M, Kojima M, Goto K, Hara M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Okusaka T.

Chemotherapy. 2013;59(1):74-8. doi: 10.1159/000351103. Epub 2013 Jul 18.

PMID:
23867634
8.

[A case of neuroendocrine carcinoma of the duodenal papilla].

Toshiyama R, Yokoyama S, Hashimoto K, Takeda M, Tokuoka M, Matsuyama J, Ide Y, Morimoto T, Fukushima Y, Nomura T, Kodama K, Shiba I, Takeda M, Sasaki Y.

Gan To Kagaku Ryoho. 2013 Nov;40(12):1762-4. Japanese.

PMID:
24393914
9.

[Prospects for standardization of surgical procedures for carcinoma of the pancreas].

Wataru K.

Nihon Geka Gakkai Zasshi. 2003 May;104(5):412-21. Review. Japanese.

PMID:
12774526
10.

Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.

Filosso PL, Ruffini E, Oliaro A, Rena O, Casadio C, Mancuso M, Turello D, Cristofori RC, Maggi G.

J Thorac Cardiovasc Surg. 2005 Apr;129(4):819-24.

11.

The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.

Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL.

Cancer Res. 2012 Nov 15;72(22):5683-91. doi: 10.1158/0008-5472.CAN-12-2102. Epub 2012 Sep 17.

12.

Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.

Asayama M, Yamada-Murano T, Hara H, Ooki A, Kurosumi M, Yamaguchi K.

Jpn J Clin Oncol. 2014 Feb;44(2):186-90. doi: 10.1093/jjco/hyt193. Epub 2013 Dec 22.

PMID:
24367043
13.

[Treatment Strategy for Non-Functional Pancreatic Neuroendocrine Tumors (P-NETs) at Kurume University Hospital].

Kawashima Y, Ishikawa H, Hisaka T, Okuda K, Akagi Y.

Gan To Kagaku Ryoho. 2016 Jan;43(1):107-10. Japanese.

PMID:
26809536
14.

Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.

Fiebrich HB, Siemerink EJ, Brouwers AH, Links TP, Remkes WS, Hospers GA, de Vries EG.

Oncologist. 2011;16(6):783-7. doi: 10.1634/theoncologist.2010-0222. Epub 2011 Apr 11.

15.

A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.

Ochiai T, Komiyama S, Ikoma H, Kubota T, Nakanishi M, Ichikawa D, Kikuchi S, Fujiwara H, Sakakura C, Kokuba Y, Sonoyama T, Otsuji E.

Int J Clin Oncol. 2010 Aug;15(4):423-7. doi: 10.1007/s10147-010-0051-z. Epub 2010 Mar 11.

PMID:
20221660
16.

Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T.

J Gastrointest Surg. 2009 Jan;13(1):85-92. doi: 10.1007/s11605-008-0650-4. Epub 2008 Aug 13.

PMID:
18704593
17.
18.

Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy.

Zhu Y, Li Q, Gao J, He Z, Sun R, Shen G, Zhang H, Xia W, Xu J.

Breast J. 2013 Jul-Aug;19(4):382-7. doi: 10.1111/tbj.12121. Epub 2013 May 31.

PMID:
23721399
19.

Surgery for mucin-producing pancreatic tumor.

Yasuda H, Takada T, Amano H, Yoshida M.

Hepatogastroenterology. 1998 Nov-Dec;45(24):2009-15.

PMID:
9951855
20.

[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].

Nakayama N, Tanabe S, Koizumi W, Higuchi K, Sasaki T, Nakatani K, Shimoda T, Nishimura K, Kobayashi N, Mitomi H, Saigenji K.

Gan To Kagaku Ryoho. 2006 Nov;33(11):1641-4. Japanese.

PMID:
17108732

Supplemental Content

Support Center